T-cell-directed cancer vaccines mechanisms of immune escape and immune tolerance

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 511-523

  Phan, Giao Q ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immune escape; Immune tolerance; Immunotherapy; Melanoma; T lymphocyte; Vaccines

Indexed keywords

CANCER VACCINE;

HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; REVIEW; T LYMPHOCYTE;

CANCER VACCINES; HUMAN; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0035346802     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.511     Document Type: Article

References (170)

1. MARCHAND M, WEYNANTS P, RANKIN E et a!.-. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int.J. Cancer(1995) 63 883-885.
2. CORMIER JN, SALGALLER ML, PREVETTE T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sei. Am. (1997) 3 37-44. One of the first demonstrations that a class I-restricted epitope alone can induce T-cell responses in vivo.
3. MCRAE BL, VANDERLUGT CL, DAL CANTO MC, MILLER SD Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp. Med. (1995) 182 75-85-
4. NESTLE FO, ALIJAGIC S, GILLIET M et al Vaccination of melanoma patients with peptide- or tumor lysate- ' pulsed dendritic cells. Mature Med. (1998) 4 328-332.
5. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER D étal Immunologie and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with mctastatic melanoma. Nature Med. (1998) 4 321-327.
6. SALGALLER ML, MARINCOLA FM, CORMIER JN, ROSENBERG SA Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic pcptidcs. Cancer Res. (1996) 56 4749-4757. One of the first demonstrations that a class I-restricted epitope alone can induce T-cell responses in vivo.
7. THOMAS L Cellular andHumoral Aspects oj'theHypersemitive State. Hoeber, NY, USA (1959) 529.
8. BOON T, COULIE PG, VAN DEN EYNDE B Tumor antigens recognized by T cells. Immunol. Today (1997) 18 267-268.
9. ROSENBERG SA Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today(1997) 18 175-182.
10. OLD LJ, CHEN YT New paths in human cancer serology.y. Exp. Med. (1998) 187 1163-1167.
11. TOPALIAN SL, SOLOMON D, ROSENBERG SA Tumorspecific cytotysis by lymphocytes infiltrating human melanomas. J Immunol. (1989) 142 3714-3725.
12. TOPALIAN SL, ROSENBERG SA Tumor-infiltrating lymphocytes evidence for specific immune reactions against growing cancers in mice and humans. Important Adv. Oncol. (1990) 19-4l.
13. WOLFELT, KLEHMANN E, MÜLLER C, SCHUTT KH, MEYER ZUM BUSCHENFELDE KH, KNUTH A Lysis of human melanoma cells by autologous cytoh/tic T cell clones. Identification of human histoconipatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp. Med. (1989) 170 797-810.
14. KAWAKAMI Y, ZAKUT R, TOPALIAN SL, STOTTER H, ROSENBERG SA Shared human melanoma antigens. Recognition by tumor- infiltrating lymphocytes in HLA-A2.1-transfcctcd melanomas. J Immunol. (1992) 148 638-643. First comprehensive characterisation of the commonality of melanoma antigens.
15. TOPALIAN SL, KASID A, ROSENBERG SA Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes Possible mechanisms for immunotherapeutic failures. J. Immunol. (1990) 144 4487-4495.
16. WOJTOWICZ-PRAGA S Reversal of tumor-induced immunosuppression a new approach to cancer therapy [see comments]. J. Immunotber. (1997) 20 165-177.
17. MATZINGER P An innate sense of danger. Semin. Immunol. (1998) 10 399-415.
18. ZEA AH, CURTIBD, LONGO DL et at. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. CancerRes. (1995) 1 1327-1335.
19. MARINCOLA FM, RTVOLTINI L, SALGALLER ML, PLAYER M, ROSENBERG SA Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors Evidence for in vivo priming by tumor cells. J Immunother. (1996) 19 266-277.
20. D'SOUZA S, RIMOLDI D, LIENARD D, LEJEUNE F, CEROTTINIJC, ROMERO P Circulating Melan-A/Mart-l specific cytoh/tic T lymphocyte precursors In HIA-A2+ melanoma patients have a memory phenotype. Int.]. Cancer (1998) 78 699-706.
21. LAURITZSEN GF, HOFGAARD PO, SCHENCK K, BOGEN B Clonal deletion of thymocytes as a tumor escape mechanism. Int.J. Grocer (1998) 78 216-222.
22. TOES RE, BLOM RJ, OFFRINGA R, KAST WM, MELIEF CJ Enhanced tumor outgrowth after peptidc vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. (1996) 156 3911-3918.
23. VAN PARIJS L, ABBAS AK Homeostasis and self-tolerance in the immune system turning lymphocytes off. Science (1998) 280 243-248.
24. MOSKOPHIDIS D, LECHNER F, PIRCHER HP, ZINKERNAGEL RM Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 362 758-761.
25. ALEXANDER-MILLER MA, LEGGATT GR, SARIN A, BERZOFSKY JA Role of antigen, CDS and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp. Med. (1996) 184 485-492.
26. TOES RE, SCHOENBERGER SP, VAN DER VOORT El et al. Activation or frustration of anti-tumor responses by T-cell-based immune modulation. Semin. Immunol. (1997) 9 323-327.
27. EFFROS RB, PAWELEC G Replicative senescence of T cells does the Hayflick limit lead to immune exhaustion? Immunol. Today (1997) 18 450-454.
28. EFFROS RB, ALLSOPP R, CHIU CP et al. Shortened telomcrcs in the expanded CD28-CD8 cell subset in ffiV disease implicate replicative senescence in HIV pathogenesis. AIDS (.1996) 10 F17-F22.
29. ZAVAZAVA N, KRONKE M Soluble HLA class I molecules induce apoptosis in alloreactivc cytotoxic T lymphocytes. Nature Med. (1996) 2 1005-1010. [published erratum appears in Nature Med. (1996) 2(11) 1267]
30. ZAVAZAVA N Soluble HLA class I molecules biological significance and clinical implications. Mol. Med. Today (1998) 4 116-121.
31. LOFTUS DJ, SQUARCINA P, NIELSEN MB et al. Peptides derived from self-proteins as partial agonists and antagonists of human CDS T-ccll clones reactive to mclanoma/melanocyte epitope MARTl(27-35). Cancer Res. (1998) 58 2433-2439.
32. LEE K-H, WANG E, NIELSEN M-B et al. Increased vaccine-specific T cell frequency after peptide-bascd vaccination correlates with increased susceptibility to in vitro stimulation but docs not lead to tumor regression. J Immunol. (1999) 163 6292-6300.
33. NIELSEN M-B, MONSURRO' V, MIGUELSE S étal Status of activation of circulating vaccine-elicited CDS T cells. J Immunol. (2000) 465 2287-2296.
34. TOES RE, OFFRINGA R, BLOM RJ, MELIEF CJ, KÄST WM Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc, Katl. Acad. Sei. USA (1996) 93 7855-7860.
35. LEE K-H, PANELLI MC, KIM CJ et al. Functional dissociation between local and systemic immune response following peptide vaccination. J. Immunol. (1998) 161 4183-4194. Demonstration of dissociation between systemic and local immune responses.
36. POCKAJ BA, SHERRY RM, WEI JP et al Localization of 11'indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy Augmentation with cyclophosphamide and correlation with response. Cancer (.1994) 73 1731-1737. Evidence that localisation of T-cells at tumour site is necessary for tumour rejection.
37. KAMMULA US, LEE K-H, RIKER A et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclcar cells and tumor specimens. J. Immunol. (1999) 163 6867-6879.
38. VALITUTTI S, MULLER S, DESSING M, LANZAVECCHIA A Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. (1996) 183 1917-1921.
39. GERVOIS N, GUILLOUX Y, DIEZ E, JOTEREAU F Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. (1996) 183 2403-2407.
40. FUCHS EJ, MATZINGER P Is cancer dangerous to the immune system? Semin. Immunol. (1996) 8 271-280. Application of 'danger model' to cancer immunology.
41. SCHWARTZ RH A cell culture model for T lymphocyte clonal anergy. Science (1990) 248 1349-1356.
42. MATZINGER P Tolerance, danger and the extended family. Ann. Rev. Immunol. (1994) 12 991-1045.
43. JENK1NS MK, SCHWARTZ RH Antigen presentation by chemically modified splenocytes induces antigenspecific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. (1987) 165 302-319.
44. YEWDELL JW, BENNINK JR The binary logic of antigen processing and presentation to T cells. Cell (1990) 62 203-206.
45. KALAMS SA, WALKER BD The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp. Med. (1998) 188 2199-2204.
46. ZAJAC AJ, BLATTMAN JN, MURALI-KRISHNA K et al Viral immune evasion due to persistence of activated T cells without effector function. J Exp. Med. (1998) 188 2205-2213.
47. HUNG K, HAYASHI R, LAFOND-WALKER A, LOWENSTEIN C, PARDOLL D, LEVITSKY H The central role of CD4 T cells in the antitumor immune response. J. Exp. Med. (1998) 188 2357-2368.
48. TOES RE, OSSENDORP F, OFFRINGA R, MELIEF CJ CD4 T cells and their role in antitumor immune responses. J Exp. Med. (1999) 189 753-756.
49. PELLEGRINO MA, NATALI PG, NG AK et al. Unorthodox expression of IA-like antigens on human tumor cells of nonlymphoid origin Immunological properties, structural profile and clinical relevance. In Immunologie analysis Recent progress in diagnostic laboratory immunology. Nakamura RM, Dito WR, Tucker ES (Eds.), Mason, NY, USA (1982) 159-173-
50. RUBIN JT, EIAVOOD LJ, ROSENBERG SA, LOTZE MT Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. (1989) 49 7086-7092.
51. TOPALIAN SL, RIVOLTINI L, MANCINI M et al Human CD4 T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Pmc. Natl.Acad. Sei. USA (1994) 91 9461-9465.
52. BRADY MS, ECKELS DD, REE SY, SCHULTHEISS KE, LEE JS MHC class II-mediatcd antigen presentation by melanoma cells [see comments]. J. Immunother. Emphasis Tumour Immiinol. (1996) 19 387-397.
53. ARMSTRONG TD, CLEMENTS VK, OSTRAND-ROSENBERG S MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4 T lymphocytes. J. Immiinol. (1998) 160 661-666.
54. AKPORIAYEET, PANELLI MC Functional class n antigen presentation pathway in metastatic melanoma cell lines [comment]. J. Immunother. Emphasis Tumour Immiinol. (1996) 19 398.
55. PANELU MC, WANG E, SHEN S et al. Interferon Y (IFNy) gene transfer of an EMT6 tumor that is poorly responsive to IFNy stimulation increase in tumor immunogenicity is accompanied by induction of a mouse class n transactivator and class n MHC. Cancer Immiinol. Immunother. (1996) 42 99-107.
56. ZITVOGEL L, REGNAULT A, LOZIER A et al. Eradication of established murine tumors using a novel cell-free vaccine dendritic cell-derived exosomes. Nature Med. (1998) 4 594-600.
57. RIDGE JP, DI ROSA F, MATZINGER P A conditioned dendritic cell can be a temporal bridge between a CD4 T-helper and a T-killer cell [see comments]. Nature (1998) 393 474-478.
58. CROWLEY NJ, DARROW TL, QUINN-ALLEN MA, SEIGLER HF MHC-restricted recognition of autologous melanoma by tumor- specific cytotoxic T cells. Evidence for restriction by a dominant HIA-A allele J. Immiinol. (1991) 146 1692-1699.
59. ROSENBERG SA, PACKARD BS, AEBERSOLDPM e/flJ. Use of tumor-infiltrating lymphocytes and intcrleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl.J. Med. (1988) 319 1676-1680.
60. MARINCOLA FM, JAFFE EM, HICKLIN DJ, FERRONE S Escape of human solid tumors fromT cell recognition Molecular mechanisms and functional significance.Adv. Immunol. (2000) 74 181-273.
61. VAN DER BRUGGEN P, TRAVERSARIC, CHOMEZ P étal A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254 1643-1647. Identification of first melanoma antigen recognised by T-cells.
62. DE SMET C, DE BACKER O, FARAONI I, LURQUIN C, BRASSEUR F, BOON T The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Set. USA (1996) 93 7149-7153.
63. BEDFORD MT, VAN HELDEN PD Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. (1987) 47 5274-5276.
64. LITEPLO RG, KERBEL RS Reduced levels of DNA 5-mcthylcytosine in metastatic variants of the human melanoma cell line MeWo. Cancer Res. (1987) 47 2264-2267.
65. DE VRIES TJ, FOURKOUR A, WOBBES T, VERKROOST G, RUITER DJ, VAN MUIJEN GN Heterogeneous expression of immunotherapy candidate proteins gplOO, MART-1 and tyrosinasc in human melanoma cell lines and in human melanocytic lesions. Cancer Res. (1997) 57 3223-3229.
66. MARINCOLA FM, HIJAZIYM, FETSCH P et al Analysis of expression of the melanoma associated antigens MART-1 and gplOO in metastatic melanoma cell lines andlninsitu lesions.J. JraraHnoA&er. (1996) 19 192-205.
67. VENNEGOOR C, HAGEMAN P, VAN NOUHUIJS H et al. A monoclonal antibody specific for cells of the melanocyte Uncage. Am.]. Pathol. (1988) 130 179-192.
68. VENNEGOOR C, CALAFAT J, HAGEMAN P et al. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3- Int. J. Cancer (1985) 35 287-295.
69. KAWAKAMI Y, ELIYAHU S, DELGADO CH et al. Identification of a human melanoma antigen recognized by tumor- infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sei. USA (1994) 91 6458-6462.
70. KANG X, KAWAKAMI Y, EL-GAMIL M étal Identification of a tyrosinase epitope recognized by HLA-A24restricted, tumor-infiltrating lymphocytes.J. Immunol. (1995) 155 1343-1348.
71. WOLFEL T, VAN PEL A, BRICHARD V et al Two tyrosinase nonapeptides recognized on HIA-A2 melanomas by autologous cytolytic T lymphocytes. Eur.J. Immunol. (1994) 24 759-764.
72. BRICHARD VG, HERMAN J, VAN PEL A eta!. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur.J. Immunol. (1996) 26 224-230.
73. CHEN Y-T, STOCKERT E, TSANG S, COPLAN KE, OLD LJ Irnmunophenotyping of melanomas for tyrosinasc Implications for vaccine development Proc. Natl.Acad. Sei. USA (1995) 92 8125-8129.
74. KAWAKAMIY, BATTLES JK, KOBAYASHIT et al. Production of recombinant MART-1 proteins and specific antiMAKT-1 polyclonal and monoclonal antibodies use in the characterization of the human melanoma antigen MART-1. J Immunol. Methods (1997) 202 13-25-
75. SCOTT-COOMBES DM, WHAWELL SA, VIPOND MM, CRNOJEVIC L, THOMPSON JN Fibrinolytlc activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut (1993) 34 1120-1122.
76. BUSAM KJ, IVERSEN K, COPLAN KA et al Immunoreactivity for A103, an antibody to mclan-A (Mart-1), in adrenocortical and other steroid tumors. Am. J. Surg. Pathol. (1998) 22 57-63.
77. SCHEIBENEGGEN C, WEYERS I, RUITER D, WILLHAUCK M, BITTINGER A, KEILHOLZ U Expression of gplOO in melanoma métastases resected before or after treatment with IFN alpha and IL-2.J.Immunotber. (1996) 19 375-380.
78. CORMIER JN, HIJAZI YM, ABATI A et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in mctastatic melanoma in vivo. Jut. J. Cancer(1998) 75 517-524.
79. RIKER A, KANLMULA US, PANEIXI MC et al.-. Immune selection following antigen specific inununotherapy of melanoma. Surgery (1999) 126 112-120.
80. CORMIER JN, PANELLI MC, HACKETT JA et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model Int.]. Cancer(1999) 80 781-790.
81. YOSHINO I, PEOPLES GE, GOEDEGEBUURE PS, MAZIARZ R, EBERLEIN TJ Association of HER2/neu expression with sensitivity to tumor- specific CTL in human ovarian cancer.J. Immunol. (1994) 152 2393-2400.
82. + T cells and process soluble antigen. J. Immunol. (1995) 155 5427-5435.
83. JAGER E, RINGHOFFER M, KARBACH J, ARAND M, OESCH F, KNUTH A Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CDS cytotoxic-T-cell responses Evidence for immunoselection of antigen-loss variants in vivo. Int.}. Cancer (1996) 66 470-476. Clinical suggestion for immune escape.
84. FERRONE S, MARINCOLA FM Loss of HLA class I antigens by melanoma cells molecular mechanisms, functional significance and clinical relevance. Immunol. Today (.1995) 16 487-494.
85. GARRIDO F, RUIZ-CABELLO F, CABRERA T étal. Implications for immunosurveillance of altered HLA class I phenotypcs in human tumours. Immunol. Toaay(.l997) 18 89-95.
86. D'URSO CM, WANG ZG, CAO Y, TATAKE R, ZEFF RA, FERRONE S Lack of HIA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin. Invest. (1991) 87 284-292.
87. WANG Z, CAO Y, ALBINO AP, ZEFF RA, HOUGHTON A, FERRONE S Lack of HIA class I antigen expression by melanoma cells SK-MEL- 33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J. Clin. Infest. (1993) 91 684-692.
88. BICKNELL DC, ROWAN A, BOOMER WF Beta 2-microglobulin gene mutations a study of established colorcctal cell lines and fresh tumors. Proc. Katl. Acad. Sei. USA (1994) 91 4751-4756.
89. HICKLIN DJ, WANG Z, ARIENTI F, RIVOLTINI L, PARMIANI G, FERRONE S Beta2-Microglobulin mutations, HIA class I antigen loss and tumor progression in melanoma. J Clin. Invest. (1998) 101 2720-2729.
90. WANG Z, SELIGER B, MIKE N, MOMBURG F, KNUTH A, FERRONE S Molecular analysis of the HIA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29- Cancer Res. (1998) 58 2149-2157.
91. WANG Z, ARIENTI F, PARMIANI G, FERRONE S Induction and functional characterization of 2-microglobulin (2-)-frce HIA class I heavy chains expressed by 2-deficient human FO-1 melanoma cells. Eur. J. Immiitiol. (1998) 28 2817-2826.
92. BICKNELL DC, KAKLAMANIS L, HAMPSON R, BODMER WF, KARRAN P Selection for beta 2-microglobulin mutation in mismatch repair-defective colorcctal carcinomas. Curr. Bio!. (1996) 6 1695-1697.
93. BENITEZ R, GODELAINE D, LOPEZ-NEVOT MA et al. Mutations of the z-microglobulin gene result in a lack of HIA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens (.1998) 52 520-529.
94. MARINCOLA FM, SHAMAMIAN P, ALEXANDER RB et al Loss of HIA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. (1994) 153 1225-1237.
95. TORRES MJ, RUIZ-CABELLO F, SKOUDY A etal Loss of an HIA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens (1996)47 372-381.
96. KOOPMAN LA, MULDER A, CORVER WE et al. HIA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens (1998) 51 623-636.
97. RIVOLTINI L, BARACCHINI KG, VIGGIANO V et al. Quantitative correlation between HIA Class I allelc expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. (1995) 55 3149-3157.
98. WANG Z, MARINCOLA FM, RIVOLTINI L, PARMIANI G, FERRONE S Selective human leukocyte antigen (HIA)-A2 loss caused by aberrant prc-mRNA splicing in 624MEL28 melanoma cells. J Exp. Med. (1999) 190 205-215.
99. MARINCOLA FM, SHAMAMIAN P, SIMONIS TB et al Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J. Immtinother. Emphasis Tumour Immunol. (1994) 16 13-23.
100. KIM CJ, TAUBENBERGER JK, SIMONIS TB, WHITE DE, ROSENBERG SA, MARINCOLA FM Combination therapy with Interferon-gamma and Interlcukln-2 for the treatment of metastatic melanoma. J. Immunotber. (1996) 1900-58.
101. AMIOT L, ONNO M, RENARD I étal HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens (1996) 48 609-614.
102. PAUL P, ROUAS-FREISS N, KHALIL-DAHER I et al. HIA-G expression in melanoma a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sei. USA (1998) 95 4510515.
103. LJUNGGREN HG, KARRE K Host resistance directed selectively against H-2-deficient h/mphoma variants. Analysis of the mechanism. J. Exp. Med. (1985) 162 1745-1759-
104. LOPEZ-BOTET M, MORETTA L, STROMINGER J NK-cell receptors and recognition of MHC class I molecules. Immunol. Today(.199S) 17 212-214.
105. BRAUD VM, ALLAN DS, O'CALLAGHAN ÇA et al. HIA-E binds to natural killer cell receptors CD94/NKG2A, B and C [see comments]. Nature (1998) 391 795-799.
106. BRAUD V, JONES EY, MCMICHAEL A The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. EUT.]. Immunol. (1997) 27 1164-1169.
107. LANIER LL Follow the leaden NK cell receptors for classical and nonclasslcal MHC class I. Cell (1998) 92 705-707.
108. MAIO M, ALTOMONTE M, TATAKE R, ZEFF RA, FERRONE S Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin. Invest. (1991) 88 282-289.
109. SCHRIER PI, PELTENBURG LT Relationship between myc oncogene activation and MHC class I expression. Adv. Cancer Res. (1993) 60 181-246.
110. PORGADOR A, MANDELBOIM O, RESTIFO NP, STROMINGER JL Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells implications for cancer immunothcrapy. Proc. Nail. Acad. Sei. USA (1997) 94 13140-13145.
111. PENDE D, ACCAME L, PARETI L et al. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I allcles. Eur.J. Immunol. (1998) 28 2384-2394.
112. RESTIFO NP, ESQUIVEL F, KAWAKAMIY eta!. Identification of human cancers deficient in antigen processing. J. Exp. Med. (1993) 177 265-272.
113. SANDA MG, REST1FO NP, WALSH JC et al- Molecular characterization of defective antigen processing in human prostate cancer. J Nat!. Cancer Inst. (1995) 87 280-285.
114. MAEURER MJ, GOLLIN SM, MARTIN D et al Tumor escape from immune .recognition lethal recurrent melanoma in a patient associated with downrcgulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. (1996) 98 1633-1641.
115. ROWE M, KHANNA R, JACOB ÇA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstcln-Barr virus latent membrane protciii-1 coordinate up-regulation of peptide transporter and HIA-class I antigen expression. EUT.]. Immunol. (1995) 25 1374-1384.
116. WHITE RL Excess risk of colon cancer associated with a polymorphism of the APC gene? [Editorial; comment]. Cancer Res. (1998) 58 4038-4039.
117. CROMME FV, VAN BOMMEL PF, WALBOOMERS JM et al Differences in MHC and TAP-1 expression in cervical cancer lymph node métastases as compared with the primary tumours. Br.J. Cancer (1994) 69 1176-1181.
118. HILDERS CG, MUNOZ IM, NOOYEN Y, FLEUREN GJ Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Cytiecol. Oncol. (1995) 57 366-375.
119. KAGESHITA T, HIRAI S, ONO T, HICKLIN DJ, FERRONE S Downregulation of HIA class I antigen processing molecules in malignant melanoma association with disease progression. Am.]. Palbol. (1999) 154 745-754.
120. VAN DRIEL WJ, TJIONG MY, HILDERS CG, TRIMBOS BJ, FLEUREN GJ Association of allele-speclfic HIA expression and histopathologlc progression of cervical carcinoma. Gynecol. Oncol. (1996) 62 331.
121. HILDERS CG, HOUBIERS JG, KRUL EJ, FLEUREN GJ The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am.]. Clin. Pathol. (1994) 101 5-12.
122. OTTESEN SS, KIELER J, CHRISTENSEN B Changes in HLA A, B, C expression during 'spontaneous' transformation of human urothelial cells in vivo. Eur. J. Cancer Clin. Oncol. (1987) 23 991-995.
123. TOMITA Y, MATSUMOTO Y, NISHIYAMA T, FUJIWARA M Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma. J Pathol. 0990) 162 157-164.
124. TOMITA Y, NISHIYAMA T, FUJIWARA M, SATO S Immunohistochcmical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells hi renal cell cancer. Br.J. CVwar(1990) 62 354-359.
125. LEHMANN F, MARCHAND M, HAINAUT P et al. Differences in the antigens recognized by cytolytic T cells on two successive métastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. (1995) 25 340-347.
126. IKEDA H, LETHE B, LEHMANN F et al. Characterization of an antigen that is recognized on a melanoma showing partial HIA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 6 199-208.
127. NISTICO' P, MOTTOLESE M, MAMMI C et al. Low frequency of ErbB-2 proto-oncogene overexpression in human leukocyte antigen A2 positive breast cancer patients. J Nat!. CancerInst. (1997) 89319-321.
128. YOONG KF, MCNAB G, HUBSCHER SG, ADAMS DH Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothclium in human hepatocellular carcinoma. J. Immunol. (1998) 160 3978-3988.
129. VANKY F, WANG P, PATARROYO M, KLEIN E Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol. Immunotber. (1990) 31 19-27.
130. CAO X, CHEN G, HE L, ZHANG W, YD Y, WANG J Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL>2, IL-4 or IL-6 gene. J. Cancer Res. Clin. Oncol. (1997) 123 602-608.
131. LEFOR AT, FABIAN DF Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murinc model. J. Surg. Res. (1998) 75 49-53.
132. BUDINSKY AC, BRODOWICZ T, WILTSCHKE C et al. Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cells in vitro. Int.J. Cancer(.1997) 71 1086-1090.
133. KRUNKOSKY TM, FISCHER BM, AKLEY NJ, ADLER KB Tumor necrosis factor alpha (TNF-cO-induced ICAM-1 surface expression in airway epithelial cells in vitro Possible signal transduction mechanisms. Ann. NY Acad. Sei. (1996) 796 30-7 30-37.
134. KILGORE KS, SHEN JP, MILLER BF, WARD PA, WARRENJS Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1.J. Immunol. (1995) 155 1434-1441.
135. MORTARINI R, BELLI F, PARMIANI G, ANICHINI A Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells comparison with anti-proliferative activity by rILl-beta, rTNF-alpha, rIFN-gamma, r!L4 and their combinations. Int.J. Owcer(1990) 45 334-341.
136. KRUTMANN J, KOCK A, SCHAUER E et al. Tumor necrosis factor beta and ultraviolet radiation are potent regulators of human keratinocyte ICAM-1 expression. J Invest. Dennatol. (1990) 95 127-131.
137. KITSUKI H, KATANO M, IKUBO A et al. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion Role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clin. Immunol. Immunopatbol. (1996) 78 283-290.
138. VUE FY, DUMMER R, GEERTSEN R étal.-. Intcrlcukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HIA class-II and ICAM-1 molecules. Int.]. Cancer(.\997) 71 630-637.
139. DECKER JC, DUMMER R, HARTMANN AA, BURG G, SCHMIDT RE Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha functional consequences on cell-mediated cytotoxicity. J. Immunol. (1991) 147 4398-4401.
140. GV7IN JL, GERCEL-TAYLOR C, TAYLOR DD, EISENBERG B Role of LFA-3, ICAM-1 and MHC class I on the sensitivity of human tumor cells to 1AK cells. J. Surg. Res. (1996) 60 129-136.
141. WEBB DS, MOSTOWSKI HS, GERRARD TL Cytoklncinduced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocytemediated lysis. J Immunol. (1991) 146 3682-3686.
142. AKELLA R, HALL RE Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cy to lys is evidence for additional ligands for effector cell beta Integrals. Eitr.J. Immunol. (1992) 22 1069-1074.
143. GABRILOVICH DI, CHEN HL, GIRGIS KR etal Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published erratum appears in Nature Med. (1996) 2(11) 1267]. Nature Med. (1996) 2 1096-1103.
144. FIORENTINO DF, BOND MW, MOSMANN TR Two types of mouse T helper celL Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J. Exp. Med. (1989) 170 2081-2095.
145. VIEIRA P, DE WAAL-MALEFYT R, DANG MN et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones Homology to EpsteinBarr virus open reading frame BCRFI. Proc. Natl. Acad. Sei. USA (1991) 88 1172-1176.
146. TAGA K, TOSATO G IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol. (1992) 148 1143-1148.
147. DUMMER W, BASTIAN BC, ERNST N, SCHANZLE C, SCHWAAF A, BROCKER EB Intcrlcukin-10 production in malignant melanoma preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int.]. Omcer(1996) 66 607-610.
148. GERARD CM, BRUYNS C, DELVAUX A et al Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in R16 melanoma cells. Hum. Gene Tber. (1996) 7 23-31.
149. ZHENG LM, OJCIUS DM, GERAUD F et al Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. (1996) 184 579-584.
150. HUANG S, ULLRICH SE, DAR-ELI M Regulation of tumor growth and metastasis by intcrlcukin-10 the melanoma experience. J Interferon Cytokine Res. (1999) 19 697-703.
151. KUNDUN, BEATYTL, JACKSON MJ, FULTON AM Antimctastatic and antitumor activities of intcrleukin-10 in a murine model of breast cancer. J. Natl. Cancer Inst. (1996) 88 536-541.
152. STEARNS ME, RHIM J, WANG M Interleukin-10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix mctalloproteinase (MMP>2/MMP-9 secretion. Clin. Cancer. Res. (1999) 5 189-196.
153. KAUFMAN HL, RAO JB, IRVINE KR, BRONTE V, ROSENBERG SA, RESTIFO NP Interleukin-10 enhances the therapeutic effectiveness of a rccombinant poxvirus-based vaccine hi an experimental murine tumor model. J. Imtnunotber. (1999) 22 48996.
154. SANTIN AD, HERMONAT PL, RAVAGGI A et al. Intcrlcukin-10 increases Thl cytokine production and cytotoxic potential in human papilloma virus-specific CDS cytotoxic T lymphocytes. J. Virol. (2000) 74 4729737.
155. CLERICI M, SHEARER GM The Thl-Th2 hypothesis of HIV infection new insights. Immunol. Today (1994) 15 575-581.
156. BEIXONE G, ASTE-AMEZAGA M, TRINCHIERI G, RODECK U Regulation of NK cell functions by TGF-beta 1. J. Immunol. (1995) 155 1066-1073.
157. WOJTOWICZ-PRAGA S, VERMA UN, WAKEFIELD L et al. Modulation of Bl6 melanoma growth and metastasis by anti-transforming growth factor beta antibody and intcrlcukin-2.[published erratum appears in J. Immunolber. Emphasis Tumour Immunol. (1996) 19 386]. J. Immunotber. (1996) 19 169-175-
158. VAN BELLE P, RODECK U, NUAMAH I, HALPERN AC, ELDER DE Melanoma-associated expression of transforming growth factor-beta isoforms. Am. J. Patbol. (1996) 148 1887-1894.
159. SCHMID P, ITIN P, RUFLI T In situ analysis of transforming growth factor-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta Type II receptor expression in malignant melanoma. Carcinogenesis (1995) 16 1499-1503.
160. MORETTI S, PINZI C, BERTI E etal-.In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integral expression. Melanoma Res. (1997) 7 313-321.
161. SCHMID P, ITIN P, RUFLI T In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta Type U receptor expression in basal cell carcinomas. Br. J. Dennatol. (1996) 134 1044-1051.
162. RODECK U, MELBER K, KATH R et al Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J. Invest. Dcrmatol, (1991) 97 20-26.
163. GORSCH SM, MEMOLI VA, STUKEL TA, GOLD LI, ARRICK BA Imruunohistochcniical staining for transforming growth factor beta 1 associates with disease progression hi human breast cancer. Cancer Res. (1992) 52 6949-6952.
164. D'ORAZIO TJ, NIEDERKORN JY A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol. (1998) 160 2089-2098.
165. TENSEN CP, VERMEER MH, VAN DER STOOP PM et al Epidermal intcrfcron-gamma induciblc protcin-10 (IP-10) and monokine induced by ganuna-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest. Dermatol. (1998) 111 222-226.
166. PIALI L, WEBER C, LAROSA G et al.-. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Ettr. J. Immunol. (1998) 28 961-972.
167. SGADARI C, FARBER JM, ANGIOLILLO AL et al Mig, the monokinc induced by intcrfcron-gamma, promotes tumor necrosis in vivo. Blood(1997) 89 2635-2643.
168. FARBER JM Mig and IP-10 CXC chemokines that target lymphocytes. J Letikoc. Biol. (1997) 61 246-257.
169. HAHNE M, RIMOLDI D, SCHROTER M et al Melanoma cell expression of Fas (Apo-l/CD95) ligand implications for tumor immune escape. Science (1996) 274 1363-1366.
170. RIMOLDI D, MUEHLETHALER K, ROMERO P etal Limited involvement of the Fas/FasL pathway in melanomainduced apoptosis of tumor-specific T cells. Proc. Cancer Vacc. Week (1998) 1 3-82.